Funded Projects › HORIZON
VICT3R · Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research
VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of animals used in experimental studies performed during the nonclinical drug and chemical safety evaluation by replacing the animals of the concurrent controls groups (CCGs) with Virtual Control Groups (VCGs). These VCGs will be generated by means of state-of-the-art statistical or artificial intelligence (AI) approaches that optimally exploit the wealth of historical data from control animals accumulated over decades by pharmaceutical companies and other relevant industrial and academic sectors. The VCG concept was conceived and prototyped during the recently finished eTRANSAFE IMI2 project for its application in the nonclinical safety assessment of the pharmaceutical industry. A preliminary evaluation of the VCG concept carried out in the eTRANSAFE project demonstrated that it is generally feasible, yet scientifically and operationally challenging and must therefore be refined before its adoption for regulatory hazard and risk assessment. The main challenges consist of adequate data collection and curation, identification of key variables to achieve optimal matching between VCGs and CCGs, and validation of procedures including compliance with Good Laboratory Practice (GLP). These challenges will be systematically tackled in VICT3R for achieving the full development and regulatory acceptance of the VCG concept. VICT3R will collect, curate and analyse large data sets of control animals from different species to produce a large high-quality database. The database will be made available to VICT3R partners, regulators, and policy makers with the purpose to allow maturation of the VCG concept and to prove its validity, reproducibility and robustness. While VICT3R will be primarily focused on repeated dose toxicity studies, the extension of the VCG concept to other types of studies involving animals will also be tackled. VICT3R will promote that its database and software platform is maintained and expanded long term.
Consortium · 45 organisations
UNIVERSIDAD POMPEU FABRA
ES · €2,552,250
MERCK LIFE SCIENCE KGAA
DE
PHUSE CUIDEACHTA FAOI THEORAINN RATHAIOCHTA
IE · €621,500
AMGEN RESEARCH (MUNICH) GMBH
DE
ASTRAZENECA UK LIMITED
UK
ABBVIE INC
US
SANOFI-AVENTIS DEUTSCHLAND GMBH
DE
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
UK
TAKEDA PHARMACEUTICALS INTERNATIONAL AG
CH
UCB BIOPHARMA
BE
Janssen Research & Development, LLC
US
MERCK ELECTRONICS KGAA
DE
SYNCWORK AKTIENGESELLSCHAFT
DE · €835,000
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
DE · €1,457,125
NOVARTIS PHARMA AG
CH
VRIJE UNIVERSITEIT BRUSSEL
BE · €639,750
IPSEN INNOVATION SAS
FR
F. HOFFMANN-LA ROCHE AG
CH
MEDBIOINFORMATICS SOLUTIONS SL
ES · €686,250
ORION OYJ
FI
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG
DE
Incyte Corporation
US
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN
DE
Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A.
IT
TECHNISCHE UNIVERSITAT DORTMUND
DE · €456,125
BASF SE
DE
BOEHRINGER INGELHEIM INTERNATIONALGMBH
DE
GRITSYSTEMS AS
DK · €1,813,250
ORGANON SRL
RO · €751,875
JANSSEN VACCINES & PREVENTION BV
NL
INSTEM SCIENTIFIC LIMITED
UK
INSTITUT SERVIER DE MEDECINE TRANSLATIONNELLE
FR
UNIVERSITAT KONSTANZ
DE · €248,750
PFIZER INC
US
ZOETIS BELGIUM SA
BE
BAYER AKTIENGESELLSCHAFT
DE
NOVO NORDISK A/S
DK
DECIPHEX LIMITED
IE · €1,211,250
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
ES · €940,625
CAATevents gGmbH
DE · €376,250
BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION
ES · €934,750
BRISTOL-MYERS SQUIBB COMPANY CORP
US
JANSSEN PHARMACEUTICA NV
BE
INCYTE BIOSCIENCES DISTRIBUTION B.V
NL
MERCK HEALTHCARE KGAA
DE
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.